Next Article in Journal
Derlin-3 Is Required for Changes in ERAD Complex Formation under ER Stress
Next Article in Special Issue
How Periodontal Disease and Presence of Nitric Oxide Reducing Oral Bacteria Can Affect Blood Pressure
Previous Article in Journal
T Cell Immunity to Bacterial Pathogens: Mechanisms of Immune Control and Bacterial Evasion
Previous Article in Special Issue
The Redox-Sensitive Na/K-ATPase Signaling in Uremic Cardiomyopathy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 17
10.3390/ijms21176147
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Redox Signaling and Regional Heterogeneity of Endothelial Dysfunction in db/db Mice

by
Nada A. Sallam
1 and
Ismail Laher
2,*
1
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr Al-Aini Street, Cairo 11562, Egypt
2
Department of Anesthesiology, Faculty of Medicine, Pharmacology and Therapeutics, The University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(17), 6147; https://doi.org/10.3390/ijms21176147
Submission received: 28 July 2020 / Revised: 15 August 2020 / Accepted: 21 August 2020 / Published: 26 August 2020
(This article belongs to the Special Issue Redox Regulation of Cardiovascular Metabolism and Inflammation)
Browse Figures
Versions Notes

Abstract

:
The variable nature of vascular dysfunction in diabetes is not well understood. We explored the functional adaptation of different arteries in db/db mice in relation to increased severity and duration of diabetes. We compared endothelium-dependent and -independent vasodilation in the aortae, as well as the carotid and femoral arteries, of db/db mice at three ages in parallel with increased body weight, oxidative stress, and deterioration of glycemic control. Vascular responses to in vitro generation of reactive oxygen species (ROS) and expression of superoxide dismutase (SOD) isoforms were assessed. There was a progressive impairment of endothelium-dependent and -independent vasorelaxation in the aortae of db/db mice. The carotid artery was resistant to the effects of in vivo and in vitro induced oxidative stress, and it maintained unaltered vasodilatory responses, likely because the carotid artery relaxed in response to ROS. The femoral artery was more reliant on dilation mediated by endothelium-dependent hyperpolarizing factor(s), which was reduced in db/db mice at the earliest age examined and did not deteriorate with age. Substantial heterogeneity exists between the three arteries in signaling pathways and protein expression of SODs under physiological and diabetic conditions. A better understanding of vascular heterogeneity will help develop novel therapeutic approaches for targeted vascular treatments, including blood vessel replacement.

1. Introduction

The high morbidity and mortality rates in diabetic patients are largely due to cardiovascular complications [1]. Endothelial dysfunction is a key factor in diabetic vascular complications [2,3], as the endothelium regulates most aspects of vascular homeostasis including blood flow, blood clotting, angiogenesis, and inflammatory response [4]. Endothelium-dependent vasodilatation is an independent predictor of cardiovascular events and death in diabetic patients [5,6,7].
Although the majority of studies in diabetic subjects or animal models reported reduced endothelial-dependent vasodilatation [2,8,9], some showed unaltered responses [10,11,12] while others reported enhanced vasodilatation [13,14,15]. These discrepancies can be attributed to differences in species, diabetes severity, the signaling pathway examined, and/or different experimental methods. Even when using the same species and strain such as db/db mice (a commonly used model of type 2 diabetes), endothelium-dependent, acetylcholine (ACh)-induced vasodilatation was reduced in the aorta [16], mesenteric arteries [17], coronary artery [18], and coronary arterioles [19], but not in gracilis muscle arterioles [20]. It is plausible that different vascular beds serving specialized functions via specific signaling pathways function differently under physiological conditions, and they likely respond differently to pathophysiological stimuli. Diabetes and atherosclerosis target specific regions in the vasculature [21], even though all vascular beds are exposed to the same systemic abnormalities of hyperglycemia, oxidative stress, and hyperlipidemia associated with these diseases.
There are several mechanisms that link hyperglycemia to vascular injury, including increased oxidative stress [22]. Elevated levels of biomarkers of oxidative stress were reported in diabetic patients [1,23] and animal models of diabetes [24,25,26]. There are several sources of reactive oxygen species (ROS) in the vasculature, including nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), cyclooxygenase (COX), uncoupled endothelial nitric oxide synthase (eNOS), and mitochondrial respiratory chain enzymes; ROS are generated by endothelial cells, vascular smooth muscle cells (VSMCs), and infiltrating neutrophils [27,28,29]. The presence of multiple sources of ROS suggests that ROS are essential cellular components that regulate vital functions via their interactions with potassium channels, calcium signaling, and various kinases [30,31,32,33,34].
This study compared endothelium-dependent and -independent vasodilatation of three conduit arteries: the aorta, as well as the carotid and femoral arteries, as related to deterioration in glycemic control and increases in oxidative burden in db/db mice at three ages. Importantly, these arteries were isolated from the same animal and examined under identical experimental conditions. Understanding these regional differences will improve our understanding of vascular homeostasis and guide the development of novel therapeutic approaches based on vascular heterogeneity.

2. Results

2.1. Age-Related Changes in Body Weight, Glycemic Control, and Systemic Oxidative Stress Biomarkers in db/db Mice

At the age of 6–8 weeks old, db/db mice weighed more than control mice (30.74 ± 0.37 g vs. 20.67 ± 0.34 g, p < 0.05). Although their fasting plasma glucose levels were not different from control mice (5.68 ± 0.31 mM vs. 4.36 ± 0.15 mM, p > 0.05), they exhibited impaired glucose tolerance (Figure 1a) and hyperinsulinemia (Figure 1b) compared to control mice. However, their plasma levels of 8-isoprostane were not significantly different from control mice (Figure 1c).
As db/db mice got older (10–14 weeks old) and more obese (45.87 ± 0.65 g vs. 27.96 ± 0.29 g), they developed hyperglycemia (31.54 ± 1.33 mM vs. 5.03 ± 0.23 mM, p < 0.05), with a further deterioration in glucose tolerance (Figure 1a) and an elevation in plasma 8-isoprostane levels (a biomarker of systemic oxidative stress) (Figure 1c). When db/db mice were 16–20 weeks old, they had increased plasma 8-isoprostane levels, indicating higher levels of systemic oxidative stress (Figure 1c), and an age-related deterioration of glycemic control; the area under the curve for glucose (AUCglucose) for db/db mice increased from 477% to 546% (p < 0.05) compared to their age-matched controls (Figure 1a). Although, db/db mice remained hyperinsulinemic at all the ages studied, as indicated by their fasting insulin levels and AUCinsulin, their ability to secrete insulin decreased from 540% (six weeks old) to 305% (10 weeks old) then 178.1% (16 weeks old), compared to age-matched control mice (Figure 1b). In contrast, control mice showed an age-dependent increase in body weight, but otherwise maintained steady levels for all other measured metabolic parameters.

2.2. Age-Related Changes in Endothelium-Dependent Vasodilatation in Aortae but not in Carotid or Femoral Arteries of db/db Mice

As described above, db/db mice showed age-related increases in body weight, fasting plasma glucose, and plasma 8-isoprostane, with deterioration in glycemic control and insulin secretion reflecting the progression of metabolic dysfunction associated with diabetes. In parallel with the progression of diabetic status, the aortae of db/db mice (6–8 weeks old) exhibited a small but significant impairment in vasodilatory response to ACh, which deteriorated further with age in terms of maximum response (Emax: db/db (6–8 weeks) = 71.59% ± 1.51%, db/db (10–14 weeks) = 53.4% ± 2.06%, and db/db (16–20 weeks) = 24.34% ± 1.84%, p < 0.05; Figure 1d), but not sensitivity (−log half maximal effective concentration (EC50): db/db (6–8 weeks) = 7.1 ± 0.05 M, db/db (10–14 weeks) = 7.3 ± 0.1 M, and db/db (16–20 weeks) = 7.1 ± 0.2 M, p > 0.05; Figure 1d). However, the vasodilatory response to ACh was preserved in carotid arteries of db/db mice in the three age groups examined (Figure 1e). ACh-induced vasodilatation was impaired in the femoral arteries of db/db mice (6–8 weeks old); Emax: db/db (6–8 weeks) = 64.18% ± 2.34% vs. control (6–8 weeks) = 84.79% ± 2.24%, p < 0.05), but did not deteriorate further with age (Emax: db/db (6–8 weeks) = 64.18% ± 2.34%, db/db (10–14 weeks) = 56.75% ± 1.77%, db/db (16–20 weeks) = 66.96 ± 1.2%, p > 0.05; Figure 1f).

2.3. Preserved Endothelium-Dependent Vasodilatation in Carotid Arteries of db/db Mice in the Presence of Increased Oxidative Burden

Despite increases in body weight, hyperglycemia, and oxidative stress in db/db mice, the vasodilatory responses to ACh were preserved in the carotid arteries of db/db mice in the three age groups (Figure 1e), in contrast to the progressive impairment of ACh-induced vasodilatation in the aortae (Figure 1d). We explored several possibilities that could underlie this differential adaptation. When carotid arteries and aortae of control mice were challenged with xanthine and xanthine oxidase as an exogenous source of ROS, the vasodilatation to ACh was impaired in the aortae (Emax: 57.75% ± 2.85% vs. 73.45% ± 1.27%, p < 0.05; −log EC50: 7.06 ± 0.04 M vs. 6.78 ± 0.12 M, p <0.05; Figure 2a,c), while the maximum vasodilator response in the carotid arteries remained unaffected (Figure 2b,d); there were minor reductions in sensitivity (−log EC50: 8.48 ± 0.04 M vs. 8.12 ± 0.15 M), indicating altered receptor-activated pathways. We also preincubated the aortic and carotid rings with diethyldithiocarbamate (DCC), an inhibitor of superoxide dismutase (SOD), to reduce the effects of the main endogenous antioxidant defense mechanism. Again, ACh-induced maximum vasodilatation was impaired in the aortae (Figure 2a,e) but not carotid arteries (Figure 2b,f). DCC did not impair sodium nitroprusside (SNP)-induced vasodilation in the aortae (Figure 2e), ruling out non-specific action of DCC on vasodilatory responses.
Preincubation of the aortic or carotid rings with L-NAME (N omega-Nitro-L-arginine methyl ester) (10−4 M) abolished ACh-induced vasodilatation in db/db and control mice at all ages studied. The aorta and carotid artery show different sensitivity and efficacy for ACh, but not for SNP (Figure 2g,h). The carotid artery is more sensitive to ACh (−log EC50: carotid = 8.49 ± 0.05 M vs. aorta = 7.54 ± 0.06 M, p < 0.05) and relaxed to a greater extent (Emax: carotid = 90.25% ± 1.04% vs. aorta = 75.52% ± 1.4%, p < 0.05). There were no differences in sensitivity or efficacy for SNP between the carotid artery and the aorta.

2.4. Signaling Pathway of Endothelium-Dependent Vasodilatation in the Carotid Artery

2.4.1. Effects of Tempol, Catalase, or Ebselen on ACh-Induced Vasodilatation

We next determined whether ACh-induced vasodilatation in the carotid artery was mediated by NOS-generated ROS, focusing on superoxide anion (O2−), hydrogen peroxide (H2O2, the more stable product of O2−), or peroxynitrite (ONOO−, the product of the reaction of NO with O2−). Carotid arteries were incubated with tempol (an O2− scavenger), catalase (an enzyme responsible for catalyzing H2O2 decomposition), or ebselen (an ONOO− scavenger) before examining ACh vasodilatory responses. Ebselen and, to a lesser extent, tempol impaired ACh-induced vasodilatation in the carotid arteries of control and db/db mice (Figure 3a), suggesting a role for ONOO− in mediating ACh-induced vasodilatation in carotid arteries.

2.4.2. Effect of Exogenous O2− or ONOO− on Pre-Constricted Aortae and Carotid Arteries

To confirm the vasorelaxant effect of ONOO− in the carotid artery, we exposed pre-constricted carotid arteries to an exogenous ONOO−-generating system (xanthine, xanthine oxidase, and a low concentration of SNP). Adding xanthine and xanthine oxidase, with or without SNP, relaxed the carotid artery (51.78 ± 6.72%) (Figure 3b). Adding either xanthine or xanthine oxidase alone did not cause vasodilatation, ruling out nonspecific effects and suggesting that vasodilatation observed in carotid arteries was mediated by O2− or O2− metabolite(s); O2− reacts with basal nitric oxide (NO). This vasorelaxant effect of xanthine and xanthine oxidase in the carotid artery was inhibited by 4-aminopyridine (4-AP) (Figure 3c), suggesting a role for Kv in mediating the vasodilatation. This treatment (xanthine + xanthine oxidase) did not relax the aorta, but adding ACh later caused vasodilation in the aorta (Figure 3d).

2.4.3. Effects of Potassium Channel Inhibitors on Endothelium-Dependent Vasodilatation in the Carotid Artery

ROS regulates vascular tone by interacting with potassium channels [32,34,35]. Four types of potassium channels are expressed in the vasculature. We preincubated carotid arteries with 4-AP to inhibit KV, glybenclamide to inhibit KATP, barium chloride to inhibit Kir, or a combination of charybdotoxin and apamin to inhibit KCa. Only 4-AP impaired ACh-induced vasorelaxation in carotid arteries (Figure 4a).
We compared the effects of 4-AP, ebselen, or their combination on ACh-induced vasorelaxation to examine if KV is the target of ONOO− in carotid arteries. Addition of 4-AP, ebselen, or their combination reduced ACh maximum response to the same magnitude (Emax: 53.59 ± 2.67%, 47.09 ± 3.57%, 48.34 ± 5.06% respectively, p > 0.05) (Figure 4b); there was no additive effect suggesting that ONOO− and Kv are components of the same pathway. Additionally, the vasorelaxant effect of xanthine and xanthine oxidase in the carotid artery was inhibited by 4-AP as described above (Figure 3c), confirming a role for Kv in mediating carotid artery vasodilatation under physiological and pathological conditions of oxidative stress.

2.5. Generalized Vascular Dysfunction in the Aortae of db/db Mice

2.5.1. Effects of Indomethacin, Apocynin, L-NAME, and Tempol on Impaired ACh-Induced Vasodilatation in the Aortae of db/db Mice

ROS can be generated from various sources in the vasculature, including NADPH oxidase, uncoupled eNOS, COX, and respiratory chain enzymes [27]. We reasoned that inhibiting the enzyme producing the greatest output of ROS in the aorta would result in the largest improvement in ACh-induced vasodilatation. The aortae of db/db mice (16–20 weeks old) were preincubated with an NOS inhibitor (L-NAME), a COX inhibitor (indomethacin), an NADPH oxidase inhibitor (apocynin), or a cell-permeable SOD mimetic (tempol) before examining ACh-induced vasodilatation. None of these treatments, including tempol (at a dose that caused maximum suppression of the O2− level in cultured VSMCs [36]), improved ACh-induced vasodilatation. L-NAME abolished the ACh-induced vasodilatation (Figure 5a).

2.5.2. Impaired Endothelium-Independent Vasodilatation in the Aortae of db/db Mice

The aortae of db/db mice showed an age-dependent progressive deterioration in endothelium-dependent, ACh-induced vasodilatation as described above. We then examined endothelium-independent vasodilatation by using SNP, a direct NO donor that bypasses the endothelium and acts directly on VSMCs. There was no difference in SNP-induced vasodilatation between control and db/db mice aged 6–8 weeks old, but the responses to SNP were blunted in 16–20-week-old db/db mice (Emax: control (16–20 weeks) = 84.38 ± 1.04% vs. db/db (16–20 weeks) = 71.0 ± 1.25%, p < 0.05) as shown in Figure 5b. To investigate if vascular dysfunction was confined to the NO/cyclic guanine monophosphate (cGMP) mediated pathway, we examined the response to isoprenaline, a β-adrenoceptor agonist that acts via the cyclic adenosine monophosphate (cAMP) pathway [37]. A reduced response to isoprenaline was also observed in the aortae of db/db mice (Emax: control (16–20 weeks) = 87.21 ± 1.83% vs. db/db (16–20 weeks) = 69.19 ± 2.02%, p < 0.05) as shown in Figure 5c.

2.6. Impaired Vasodilatation in Femoral Arteries of db/db Mice

Vasodilatory responses to ACh were impaired in the femoral arteries of db/db mice; this reduced response started at 6–8 weeks of age and did not further deteriorate with age in contrast to age-dependent losses in the aortae (Figure 1d,f). To elucidate the ACh signaling pathways in the different arteries, we preincubated arteries with indomethacin, a combination of L-NAME and indomethacin, a depolarizing concentration of KCl, or a combination of L-NAME, indomethacin, and KCl. Indomethacin did not affect ACh-induced vasodilatation in db/db or control mice. Preincubation with L-NAME plus indomethacin reduced ACh-induced vasodilatation in the femoral arteries but did not abolish it, in contrast to the aortae and carotid arteries, where L-NAME abolished the vasodilatation. This residual vasodilatation in the femoral arteries was abolished by KCl or the combination of charybdotoxin and apamin, suggesting that this component of ACh-induced vasodilatation was mediated by an endothelium-dependent hyperpolarizing factor (EDHF). Both NOS- and EDHF-mediated pathways were impaired in db/db mice (Figure 6a,b).
The contribution of the EDHF-mediated component, compared with the NOS-mediated component, was more markedly reduced in db/db mice, as reflected by reduced AUCEDHF (db/db = 24.72 ± 10.89 area units, 19.04% vs. control = 89.22 ± 7.65 area units, 40.79%, p < 0.05). The residual AUC remaining after subtracting the component attributed to EDHF should reflect the NOS-dependent component (AUCNOS), which was also reduced in db/db mice (105.08 area units) vs. control (129.48 area units). However, the relative contribution of the NOS-mediated component to total ACh-induced vasodilatation was higher in db/db (80.96%) compared with control mice (59.21%), as shown in Figure 6c. Isolating the NOS-dependent component by using KCl to eliminate the EDHF-dependent pathway showed that this depolarization-resistant pathway was also reduced in db/db mice (AUCKCl resistant: db/db = 50.12 ± 5.84 area units vs. control = 108.21 ± 7.73 area units, p < 0.05).
The sum of AUCs yielded by the KCl-resistant component plus NOS- and COX-resistant component was smaller than the total AUC of ACh-induced vasodilatation. This difference was even more pronounced in db/db mice; AUCKCl resistant (50.12 ± 5.84) + AUCL−NAME and indomethacin resistant (24.72 ± 10.89) < AUCACh (129.8 ± 11.84), suggesting that NO and EDHF have synergistic actions. As mentioned previously, ACh-induced vasodilatation in femoral arteries of db/db mice did not deteriorate with age, as was the case of EDHF-mediated vasodilatation (Figure 6d).
To identify the major enzymatic system(s) contributing to impaired ACh-induced vasorelaxation in db/db femoral arteries (16–20 weeks old), we pre-incubated the femoral arteries with indomethacin, apocynin, or a cytochrome P450 inhibitor (sulfaphenazole) before examining the responses to ACh. None of these treatments improved the vasodilatation in db/db femoral arteries and, in fact, apocynin further reduced ACh-induced vasodilatation (Figure 6e). From 16–20 weeks of age, femoral arteries of db/db mice exhibited reduced sensitivity to SNP (−log EC50: db/db (16–20 weeks) = 7.7 ± 0.05 M vs. control (16−20 weeks) = 8.28 ± 0.04 M, p < 0.05) suggesting a dysfunction at the level of VSMCs as well (Figure 6f).

2.7. Protein Expression of SOD-1, SOD-2, and SOD-3 in the Aortae, as well as Carotid and Femoral Arteries, of db/db and Control Mice

We examined protein expression of the three isoforms of SOD (cytosolic (SOD-1), mitochondrial (SOD-2), and extracellular (SOD-3)) in the aortae, as well as carotid and femoral arteries. The femoral arteries of control and db/db mice lacked expression of SOD-3, while the carotid arteries had a higher expression of SOD-3 compared to the aortae in control and db/db mice. In addition, carotid arteries expressed higher levels of SOD-1 than the aortae under diabetic conditions, while the femoral arteries of db/db mice had reduced expressions of SOD-1 and SOD-2 compared to control mice (Figure 7).

3. Discussion

Our study examined the heterogeneity in endothelium-dependent vasodilation in the aortae, as well as the carotid and femoral arteries, in db/db mice, a commonly used animal model of type 2 diabetes. The aortae of db/db mice exhibited progressive impairment in endothelial and VSMCs function, while the carotid arteries maintained unaltered functional responses, and the femoral arteries showed an early reduced EDHF-mediated vasodilatation that did not further deteriorate with age.
When db/db mice were 6–8 weeks old, they were glucose-intolerant, hyperinsulinemic, and heavier in weight, but their fasting plasma glucose levels were not higher than their age-matched controls (Figure 1a,b), suggesting that they were prediabetic, as shown in previous studies [38,39].

3.1. Aortae

The aortae of db/db mice (6–8 weeks old) exhibited a subtle but significant impairment in ACh- but not SNP-induced vasodilatation (Figure 1d), indicating early endothelial dysfunction. Endothelial dysfunction precedes the onset of frank hyperglycemia in animal [40,41] and human studies [42,43], and it is associated with obesity-associated inflammation and vascular insulin resistance [44].
The aortae of db/db mice showed progressive deterioration in ACh-induced vasodilatation with age (Figure 1d). Obesity, hyperglycemia, and insulin resistance in db/db mice could all contribute to endothelial dysfunction in the aortae via an array of mechanisms, with a key role for oxidative stress [27,45,46,47]. ROS can modulate ACh-induced vasodilatation via multiple mechanisms, including receptor binding, eNOS activation, NO bioavailability, activation of soluble guanyl cyclase, and/or interactions with contractile proteins [9,27,48]. There are several enzymatic sources of ROS in the vasculature [49]. Pre-incubation of the aortae of db/db mice (16–20 weeks old) with L-NAME, indomethacin, apocynin, or tempol did not improve ACh-induced vasodilatation (Figure 5a), suggesting that either endothelial dysfunction was irreversible in older db/db mice (16–20 weeks) or metabolic abnormalities other than oxidative stress contributed to endothelium dysfunction in the aortae of db/db mice [25,50,51], a claim that is further supported by our finding that vasodilatory responses to SNP and isoprenaline were also suppressed (Figure 5b,c), suggesting that the dysfunction involved mechanisms beyond scavenging of NO by ROS. This suggestion is also reinforced by findings that incubation with SOD was unable to improve endothelial function in old rats [52], and that catechin (an antioxidant polyphenol) could not improve endothelial function in aged atherosclerotic mice [53]. In addition, treatment with curcumin ameliorated vascular dysfunction in diabetic rats at early but not later stages of diabetes [54]. Importantly, the long-term clinical benefits of traditional antioxidants, e.g., vitamin E, C, or A, in reducing cardiovascular complications were not demonstrated [55,56,57].
To determine if the vascular dysfunction in the aortae of db/db mice was limited to the endothelium, we examined the responses to SNP, which releases a NO moiety that does not react with O2− [58]. The vasodilatory response to SNP was also impaired in the aortae of db/db mice (16–20 weeks old) (Figure 5b). Additionally, the vasodilatory responses to isoprenaline, which are cAMP-mediated [59], were reduced (Figure 5c) consistent with previous studies reporting impaired isoprenaline-induced vasodilatation in diabetic subjects [60,61,62], which was attributed to reduced Kv channel activity [62,63]. The ability of ROS to alter vascular Ca2+ regulation [64] and potassium channel activity [32], the two major regulators of vascular tone [35], may explain, in part, the progressive deterioration in endothelium-independent vasodilatation in db/db mice aortae. Our results suggest that endothelial dysfunction occurs early in diabetes and progresses to VSMC dysfunction at advanced stages.

3.2. Carotid Artery

The responses to ACh were preserved in the carotid arteries of db/db mice at the three ages examined (Figure 1e). Although there is evidence of differential adaptation of arteries in aging [52], hypoxia [65], high-fat diet-induced obesity [66], and streptozotocin-induced diabetes [67], few studies explored the mechanisms underlying vascular heterogeneity. We explored the mechanisms underlying the differential adaptation of the aorta and carotid artery in db/db mice. The local redox status may be different between the aorta and carotid artery in terms of ROS generation and/or antioxidant defense mechanisms. The production of ROS in the carotid artery might not be higher under diabetic conditions, whereas it is elevated in the aorta. Alternatively, the carotid artery might be able to upregulate its antioxidant defense mechanisms to counterbalance any elevation in local ROS production, thereby maintaining a physiological redox status. A third possibility is that the signaling pathway mediating ACh-induced vasodilatation in the carotid artery is different from that in the aorta and can buffer an increase in ROS levels.
We induced oxidative stress in the carotid arteries and aortae of control mice by using a xanthine/xanthine oxidase O2−-generating system or by inhibiting SOD, a key antioxidant enzyme, with DCC. The carotid arteries (Figure 2b,d), but not the aortae (Figure 2a,c), relaxed fully to ACh after either intervention, suggesting that carotid arteries are better able to resist oxidative stress. In support of our observation, previous studies reported enhanced O2− production in the carotid arteries of db/db mice (12 weeks old) [10,68], as well as a greater resistance to oxidative stress in the rabbit carotid artery compared to the aorta [69].
Vasodilatation to ACh was abolished by L-NAME in both aortae and carotid arteries of db/db and control mice. However, the maximal response and sensitivity to ACh, but not to SNP, were different in the carotid artery vs. the aorta (Figure 3g,h), suggesting that the ACh signaling pathway in carotid arteries is different from that in the aorta, even though both pathways are NOS-mediated. Since ACh-induced vasodilation in the carotid artery resisted increases in O2− production, and since ROS are increasingly recognized as important physiological mediators of vascular tone [70], we examined the roles of O2−, H2O2 (a more stable product of O2−), and ONOO− (the product of the reaction of NO with O2−, which occurs 3–4 times faster than the dismutation of O2− by SOD [71]) in mediating ACh-induced vasodilatation. We incubated carotid arteries with tempol, catalase, or ebselen, and we found that ebselen and, to a lesser extent, tempol impaired ACh-induced vasodilatation in carotid arteries of control and db/db mice (Figure 3a), suggesting a key role for ONOO−/O2− in mediating ACh-induced vasodilatation in carotid arteries. Adding xanthine and xanthine oxidase, with or without SNP, generating O2− or ONOO−, respectively, relaxed pre-constricted carotid arteries but not aortae (Figure 3b,d), confirming that ONOO−/O2− contributed to vasodilation in carotid arteries. Preincubation with 4-AP inhibited ACh and xanthine/xanthine oxidase-induced vasodilation in carotid arteries (Figure 3c and Figure 4a), indicating a role for KV channels in mediating vasodilatation. Preincubating carotid arteries with 4-AP, ebselen, or their combination reduced ACh maximum response to the same magnitude with no additive effect (Figure 4b) suggesting that ONOO− and KV were part of the same signaling pathway. These findings can explain, at least partially, the ability of carotid arteries of db/db mice to maintain maximal relaxation to ACh under diabetic conditions, as the product(s) of NO with O2− is/are able to relax carotid arteries. Additionally, carotid arteries had higher expression of SOD-3 compared to the aortae in control and db/db mice. Moreover, carotid arteries expressed higher protein levels of SOD-1 than aortae in db/db mice (Figure 7).
Our results extend previous findings reporting ROS as mediators of vasodilation in the vasculature [70,72,73,74,75,76,77]. Some antioxidants were shown to reduce vasodilatation; an oral antioxidant cocktail reduced exercise-induced vasodilatation in the brachial arteries of healthy subjects [78], and ebselen attenuated ACh depressor response in rats [79]. Numerous studies reported that the effects of ROS, including ONOO−, are site-dependent. ONOO− induced vasodilatation in the rabbit internal carotid artery, but not the common carotid artery [80], as well as in rat hindquarters but not pulmonary vasculature [75], and it reduced hindquarter and mesenteric but not renal vasculature resistances [74]. Furthermore, ONOO− reduced isoprenaline-induced relaxation in the hindquarters and renal circulation but not in the mesenteric vascular beds [81].

3.3. Femoral Artery

The vasodilatory response to ACh in femoral arteries was only partially inhibited by L-NAME, indicating a significant contribution of EDHF to endothelium-dependent vasodilatation (Figure 6a,b), supporting evidence of a more pronounced role for EDHF in smaller vessels [9,67,82]. Similar to the aortae and contrary to the carotid arteries, the femoral arteries of young db/db (6–8 weeks old) mice showed an early loss of ACh-induced vasodilatation. EDHF-mediated vasodilatation is impaired in diabetic animals and patients [83]. In db/db mice, EDHF was preserved in small mesenteric arteries [84], but attenuated in coronary arterioles [19]. ROS can impair EDHF via numerous mechanisms such as inhibition of intracellular calcium mobilization, inhibition of function and/or expression of the potassium channels, and inhibition of myoendothelial communication via gap junctions [83,85]. However, ACh-induced, EDHF-mediated vasodilatation in the femoral arteries of db/db mice did not further deteriorate with age despite concurrent increases in obesity, hyperglycemia, and systemic oxidative stress (Figure 1a,c and Figure 6d). Vasodilatory responses to SNP were also altered in femoral arteries of older db/db mice (16–20 weeks old), similar to changes in the aortae (Figure 5b and Figure 6f). Importantly, femoral arteries of control and db/db mice lacked expression of extracellular SOD (Figure 7), a finding that needs further study.
Among the three arteries examined, the aorta was the most vulnerable to the diabetic milieu, a finding that may be attributed, at least in part, to the fact that blood flow in the aorta, being the closest to the heart, is highly dependent on cardiac output and, therefore, aortic endothelial cells are subject to high physical stress and pulsatile flow that can increase endothelial cell loss and ignite vascular dysfunction [21]. The carotid artery maintained full relaxation under the diabetic milieu, a finding that may reflect a physiological strategy to maintain blood supply to the brain even under pathological conditions.

4. Materials and Methods

4.1. Animals

Male db/db mice (BKS.Cg-m+/+ Leprdb/J) and their age- and gender-matched normoglycemic heterozygous littermate db/m (BKS.Cg-m+/+ Leprdb/+/J) controls were purchased from Jackson Laboratory (Bar Harbor, ME, USA). The mice were housed under standard temperature, humidity, and lighting conditions in the animal facility of the University of British Columbia. The mice had free access to standard rodent chow and water. Mice were acclimatized to their housing conditions for one week before the start of experiments when the mice were six weeks old. The mice body weights and fasting blood glucose levels were measured weekly. The protocol for animal care and use was approved by the Animal Care Committee of the University of British Columbia (#A06-0308, approved on 10 November 2006).

4.2. Intraperitoneal Glucose Tolerance Test

After overnight (9:00 p.m. to 9:00 a.m.) fasting, mice were administered a glucose solution (2.0 g glucose/kg, i.p.). Blood samples were collected from the tail vein at 0, 15, 30, 60, and 120 min after glucose administration. Plasma was separated by centrifugation and stored at −76 °C for later analyses of glucose and insulin by the Glucose Assay kit (Sigma, St Louis, MO, USA) and Mouse Insulin ELISA kit (ALPCO, Salem, NH, USA), following the manufacturers’ instructions.

4.3. Plasma and Tissue Sample Collection

Mice (6, 10, or 16 weeks old) were anesthetized with pentobarbital (50 mg/kg, i.p.) combined with heparin (50 U/kg); blood samples were withdrawn from the inferior vena cava and collected into tubes containing 0.005% butylated hydroxy toluene, an antioxidant, to inhibit in vitro formation of ROS. The blood was centrifuged (10 min at 4 °C, 1000× g) and the plasma fraction was stored at −76 °C for later measurement of plasma 8-isoprostane levels using an ELISA kit (Cayman Chemical, Ann Arbor, MI, USA). The animals were euthanized by removing the heart after blood collection. The thoracic aortae, as well as the carotid and femoral arteries, were excised and kept in an ice-cold physiologic salt solution (PSS): NaCl (119 mM), KCl (4.7 mM), KH2PO4 (1.18 mM), MgSO4 (1.17 mM), NaHCO3 (24.9 mM), EDTA (0.023 mM), CaCl2 (1.6 mM), and dextrose (11.1 mM). With the aid of a dissecting microscope and microsurgery instruments, the arteries were rapidly cleared of adherent connective tissues. The dissected arteries were either snap-frozen in liquid nitrogen and stored at −76 °C for Western blot analysis or mounted in wire-myograph chambers for isometric force measurement.

4.4. Assessment of Endothelium-Dependent and-Independent Vasodilatation

Arteries were cut into 2-mm-long rings and mounted in wire-myograph chambers (Danish Myotechnology, Aarhus, Denmark) for isometric force measurement [25,86]. Each vessel chamber was filled with 5 mL PSS that was continually gassed with carbogen (95% O2 + 5% CO2) and maintained at pH 7.4 and 37 °C. The aortic, carotid, and femoral rings were gradually stretched to their optimal resting tensions (5.5, 4, or 3 mN, respectively) as determined in preliminary experiments. There were no differences in resting tensions of aorta, carotid, and femoral arteries between db/db and control mice. The PSS was replaced at 20-min intervals during the adjustment of resting tension; the arterial rings were equilibrated for at least 30 min after reaching their optimum basal tensions; they were then challenged twice with 80 mM KCl before examining the dose–response relationships.
The aortic or carotid rings were pre-constricted with a submaximal dose (producing 60–80% of the maximum response) of phenylephrine (PE), an α1-adrenoceptor agonist. In the femoral arteries, the thromboxane A2 analogue U-46619 (10−8 to 10−7 M) was used as a constrictor because PE did not yield stable contractions. After obtaining a stable contraction, ACh (10−9 to 10−5 M) was added in half-log increments in a cumulative manner to examine endothelium-dependent vasodilatation. After a 30-min washout period, the arterial rings were re-constricted with PE or U-46619, then SNP (10−10 to 10−5 M) or isoprenaline (10−9 to 10−5 M) was added to examine endothelium-independent vasodilatation. In subsets of experiments, arteries were preincubated with different vasoactive agents for 30 min before examining the responses to ACh. The mechanisms and references to the concentration of the vasoactive agents used in the vasoreactivity experiments are listed in Table S1 (Supplementary Materials). Vascular responses were recorded and analyzed by Powerlab 4/25 and Labchart 8 reader (AD Instruments, Sydney, Australia). Percentage relaxation to vasodilators (ACh, SNP, or isoprenaline) was calculated as loss of the initial PE- or U-46619-induced constriction.

4.5. Western Blot

Arteries (aorta, carotid, or femoral) from 3–5 mice (control or db/db) were pooled to yield enough protein for Western blot analysis. Frozen arteries were homogenized in ice-cold RIPA buffer (Santa Cruz, Dallas, TX, USA), and the homogenates were centrifuged at 10,000× g for 30 min at 4 °C. The protein contents of the supernatants were determined by the Coomassie Plus Protein Assay (Pierce-Thermo Fisher Scientific, Milwaukee, Wisconsin, USA). Protein samples (30–40 μg of total protein) were prepared in Laemmli sample buffer, separated by 8–10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred overnight (at 4 °C, 40 V) to nitrocellulose membranes. Membranes were then blocked for 1 h in 5% skim milk in Tris-buffered saline containing 0.1% Tween-20, washed (3 × 15 min), and incubated overnight at 4 °C with primary antibodies against SOD-1, SOD-2, SOD-3 (Santa Cruz Biotechnology, Dallas, TX, USA), or β-actin (BD Transduction Labs, Mississauga, ON, Canada) as a housekeeping protein. Membranes were triple-washed and then incubated with their corresponding horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Dallas, TX, USA) for 2 h. After washing, the blots were visualized using an enhanced chemiluminescent detection kit (Pierce-Thermo Fisher Scientific, Milwaukee, WI, USA) and ChemiDoc XRS (BioRad Laboratories, ON, Canada). Volume analyses of the protein bands were performed by Quantity One software (BioRad Laboratories, Mississauga, ON, Canada).

4.6. Statistical Analysis

Results are displayed as means ± standard error (SE). The sample size of each group is specified as (n) in the footnote for each figure. Non-linear regression, maximum response (Emax), sensitivity (EC50), area under the curve (AUC), and statistical tests were carried out using Prism version 5.0 (GraphPad Software, San Diego, CA, USA). The level of statistically significant difference was set at p < 0.05.

5. Conclusions

Our study demonstrates substantial heterogeneity and differential adaptation in endothelium- dependent vasodilation in the aortae, as well as the carotid and femoral arteries, from db/db mice that could be attributed to differences in signaling pathways and antioxidant enzyme expression. A better understanding of regional vascular heterogeneity will help in the development of targeted vascular treatments, as well as effective strategies for blood vessel replacement to combat severe cardiovascular disease related to diabetes.

Supplementary Materials

The following are available online at https://www.mdpi.com/1422-0067/21/17/6147/s1, Table S1: Vasoactive agents used in vascular reactivity experiments.

Author Contributions

Conceptualization, investigation, formal analysis, data curation, and writing—original draft preparation, N.A.S.; writing—review and editing, supervision, and project administration, I.L. All authors read and agreed to the published version of the manuscript.

Funding

This research was funded by the Egyptian Ministry of Higher Education and Scientific Research (N.A.S. received). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Acknowledgments

The authors are grateful for Baohua Wang’s technical support in Western blot experiments.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bigagli, E.; Lodovici, M. Circulating Oxidative Stress Biomarkers in Clinical Studies on Type 2 Diabetes and Its Complications. Oxidative Med. Cell. Longev. 2019, 2019, 5953685. [Google Scholar] [CrossRef]
  2. Brunner, H.; Cockcroft, J.R.; Deanfield, J.; Donald, A.; Ferrannini, E.; Halcox, J.; Kiowski, W.; Lüscher, T.F.; Mancia, G.; Natali, A.; et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J. Hypertens. 2005, 23, 233–246. [Google Scholar] [CrossRef]
  3. Shi, Y.; Vanhoutte, P.M. Macro- and microvascular endothelial dysfunction in diabetes. J. Diabetes 2017, 9, 434–449. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. McCarron, J.G.; Wilson, C.; Heathcote, H.R.; Zhang, X.; Buckley, C.; Lee, M.D. Heterogeneity and emergent behaviour in the vascular endothelium. Curr. Opin. Pharmacol. 2019, 45, 23–32. [Google Scholar] [CrossRef] [PubMed]
  5. Lerman, A.; Zeiher, A.M. Endothelial function: Cardiac events. Circulation 2005, 111, 363–368. [Google Scholar] [CrossRef] [PubMed]
  6. Stehouwer, C.D.A.; Gall, M.A.; Twisk, J.W.R.; Knudsen, E.; Emeis, J.J.; Parving, H.H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death. Diabetes 2002, 51, 1157–1165. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Nitenberg, A.; Cosson, E.; Pham, I. Postprandial endothelial dysfunction: Role of glucose, lipids and insulin. Diabetes Metab. 2006, 32, 2S28–2S33. [Google Scholar] [CrossRef]
  8. O’Driscoll, G.; Green, D.; Maiorana, A.; Stanton, K.; Colreavy, F.; Taylor, R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 1999, 33, 1506–1511. [Google Scholar] [CrossRef]
  9. De Vriese, A.S.; Verbeuren, T.J.; Van De Voorde, J.; Lameire, N.H.; Vanhoutte, P.M. Endothelial dysfunction in diabetes. Br. J. Pharmacol. 2000, 130, 963–974. [Google Scholar] [CrossRef] [Green Version]
  10. Bagi, Z.; Koller, A.; Kaley, G. Superoxide-NO interaction decreases flow- and agonist-induced dilations of coronary arterioles in Type 2 diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol. 2003, 285, H1404–H1410. [Google Scholar] [CrossRef] [Green Version]
  11. Granstam, E.; Granstam, S.-O. Involvement of Nitric Oxide in the Regulation of Regional Hemodynamics in Streptozotocin-Diabetic Rats. Physiol. Res. 2003, 52, 159–169. [Google Scholar]
  12. Fortes, Z.B.; Lerne, J.G.; Scivoletto, R. Vascular reactivity in diabetes mellitus: Role of the endothelial cell. Br. J. Pharmacol. 1983, 79, 771–781. [Google Scholar] [CrossRef] [Green Version]
  13. Szerafin, T.; Erdei, N.; Fülöp, T.; Pasztor, E.T.; Édes, I.; Koller, A.; Bagi, Z. Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus. Circ. Res. 2006, 99. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Skyrme-Jones, R.A.; Berry, K.L.; O’Brien, R.C.; Meredith, I.T. Basal and exercise-induced skeletal muscle blood flow is augmented in type I diabetes mellitus. Clin. Sci. 2000, 98, 111–120. [Google Scholar] [CrossRef]
  15. Andrew, R.; Skyrme-Jones, P.; O’brien, R.C.; Meredith, I.T. Vasodilator prostanoids, but not nitric oxide, may account for skeletal muscle hyperaemia in Type I diabetes mellitus. Clin. Sci. 2000, 99, 383–392. [Google Scholar]
  16. Yamamoto, E.; Nakamura, T.; Kataoka, K.; Tokutomi, Y.; Dong, Y.F.; Fukuda, M.; Nako, H.; Yasuda, O.; Ogawa, H.; Kim-Mitsuyama, S. Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. Biochem. Biophys. Res. Commun. 2010, 403, 258–263. [Google Scholar] [CrossRef] [PubMed]
  17. Lagaud, G.J.; Masih-Khan, E.; Kai, S.; van Breemen, C.; Dubé, G.P. Influence of type II diabetes on arterial tone and endothelial function in murine mesenteric resistance arteries. J. Vasc. Res. 2001, 38, 578–589. [Google Scholar] [CrossRef]
  18. Belmadani, S.; Palen, D.I.; Gonzalez-Villalobos, R.A.; Boulares, H.A.; Matrougui, K. Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 2008, 57, 1629–1637. [Google Scholar] [CrossRef] [Green Version]
  19. Park, Y.; Capobianco, S.; Gao, X.; Falck, J.R.; Dellsperger, K.C.; Zhang, C. Role of EDHF in type 2 diabetes-induced endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, 1982–1988. [Google Scholar] [CrossRef] [Green Version]
  20. Bagi, Z.; Erdei, N.; Toth, A.; Li, W.; Hintze, T.H.; Koller, A.; Kaley, G. Type 2 diabetic mice have increased arteriolar tone and blood pressure: Enhanced release of COX-2-derived constrictor prostaglandins. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1610–1616. [Google Scholar] [CrossRef] [Green Version]
  21. Thorin, E.; Shreeve, S.M. Heterogeneity of vascular endothelial cells in normal and disease states. Pharmacol. Ther. 1998, 78, 155–166. [Google Scholar] [CrossRef]
  22. Ding, H.; Triggle, C.R. Endothelial dysfunction in diabetes: Multiple targets for treatment. Pflugers Arch. Eur. J. Physiol. 2010, 459, 977–994. [Google Scholar] [CrossRef] [PubMed]
  23. Basu, S. F2-isoprostanes in human health and diseases: From molecular mechanisms to clinical implications. Antioxid. Redox Signal. 2008, 10, 1405–1434. [Google Scholar] [CrossRef] [PubMed]
  24. Shi, Y.; Vanhoutte, P.M. Oxidative stress and COX cause hyper-responsiveness in vascular smooth muscle of the femoral artery from diabetic rats. Br. J. Pharmacol. 2008, 154, 639–651. [Google Scholar] [CrossRef] [Green Version]
  25. Sallam, N.; Fisher, A.; Golbidi, S.; Laher, I. Weight and inflammation are the major determinants of vascular dysfunction in the aortae of db/db mice. Naunyn. Schmiedebergs Arch. Pharmacol. 2011, 383, 483–492. [Google Scholar] [CrossRef] [PubMed]
  26. Matsumoto, T.; Kobayashi, T.; Wachi, H.; Seyama, Y.; Kamata, K. Vascular NAD(P)H oxidase mediates endothelial dysfunction in basilar arteries from Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Atherosclerosis 2007, 192, 15–24. [Google Scholar] [CrossRef]
  27. Félétou, M.; Vanhoutte, P.M. Endothelial dysfunction: A multifaceted disorder (The Wiggers Award Lecture). Am. J. Physiol. Heart Circ. Physiol. 2006, 291, H985–H1002. [Google Scholar] [CrossRef]
  28. Szewczyk, A.; Jarmuszkiewicz, W.; Koziel, A.; Sobieraj, I.; Nobik, W.; Lukasiak, A.; Skup, A.; Bednarczyk, P.; Drabarek, B.; Dymkowska, D.; et al. Mitochondrial mechanisms of endothelial dysfunction. Pharmacol. Rep. 2015, 67, 704–710. [Google Scholar] [CrossRef]
  29. Gómez-Moreno, D.; Adrover, J.M.; Hidalgo, A. Neutrophils as effectors of vascular inflammation. Eur. J. Clin. Investig. 2018, 48, e12940. [Google Scholar] [CrossRef] [Green Version]
  30. Trebak, M.; Ginnan, R.; Singer, H.A.; Jourd’heuil, D. Interplay between calcium and reactive oxygen/nitrogen species: An essential paradigm for vascular smooth muscle signaling. Antioxid. Redox Signal. 2010, 12, 657–674. [Google Scholar] [CrossRef] [Green Version]
  31. Wang, Y.-X.; Zheng, Y.-M. ROS-dependent signaling mechanisms for hypoxic Ca(2+) responses in pulmonary artery myocytes. Antioxid. Redox Signal. 2010, 12, 611–623. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Gutterman, D.D.; Miura, H.; Liu, Y. Redox modulation of vascular tone: Focus of potassium channel mechanisms of dilation. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 671–678. [Google Scholar] [CrossRef] [PubMed]
  33. Chatterjee, S.; Fisher, A.B. Mechanotransduction in the endothelium: Role of membrane proteins and reactive oxygen species in sensing, transduction, and transmission of the signal with altered blood flow. Antioxid. Redox Signal. 2014, 20, 899–913. [Google Scholar] [CrossRef] [PubMed]
  34. Veit, F.; Pak, O.; Brandes, R.P.; Weissmann, N. Hypoxia-dependent reactive oxygen species signaling in the pulmonary circulation: Focus on ion Channels. Antioxid. Redox Signal. 2015, 22, 537–552. [Google Scholar] [CrossRef] [Green Version]
  35. Dunham-Snary, K.J.; Hong, Z.G.; Xiong, P.Y.; Del Paggio, J.C.; Herr, J.E.; Johri, A.M.; Archer, S.L. A mitochondrial redox oxygen sensor in the pulmonary vasculature and ductus arteriosus. Pflugers Arch. Eur. J. Physiol. 2016, 468, 43–58. [Google Scholar] [CrossRef] [Green Version]
  36. Luo, Z.; Chen, Y.; Chen, S.; Welch, W.J.; Andresen, B.T.; Jose, P.A.; Wilcox, C.S. Comparison of inhibitors of superoxide generation in vascular smooth muscle cells. Br. J. Pharmacol. 2009, 157, 935–943. [Google Scholar] [CrossRef] [Green Version]
  37. Harden, T.K. Agonist-induced desensitization of the beta-adrenergic receptor-linked adenylate cyclase. Pharmacol. Rev. 1983, 35, 5–32. [Google Scholar] [PubMed]
  38. Miike, T.; Kunishiro, K.; Kanda, M.; Azukizawa, S.; Kurahashi, K.; Shirahase, H. Impairment of endothelium-dependent ACh-induced relaxation in aorta of diabetic db/db mice--possible dysfunction of receptor and/or receptor-G protein coupling. Naunyn. Schmiedeberg’s Arch. Pharmacol. 2008, 377, 401–410. [Google Scholar] [CrossRef] [PubMed]
  39. San Martín, A.; Du, P.; Dikalova, A.; Lassègue, B.; Aleman, M.; Góngora, M.C.; Brown, K.; Joseph, G.; Harrison, D.G.; Taylor, W.R.; et al. Reactive oxygen species-selective regulation of aortic inflammatory gene expression in Type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, H2073–H2082. [Google Scholar] [CrossRef] [PubMed]
  40. Viswanad, B.; Srinivasan, K.; Kaul, C.L.; Ramarao, P. Effect of tempol on altered angiotensin II and acetylcholine-mediated vascular responses in thoracic aorta isolated from rats with insulin resistance. Pharmacol. Res. 2006, 53, 209–215. [Google Scholar] [CrossRef] [PubMed]
  41. Erdös, B.; Miller, A.W.; Busija, D.W. Alterations in KATP and KCa channel function in cerebral arteries of insulin-resistant rats. Am. J. Physiol.-Heart Circ. Physiol. 2002, 283, H2472–H2477. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Caballero, A.E.; Arora, S.; Saouaf, R.; Lim, S.C.; Smakowski, P.; Park, J.Y.; King, G.L.; LoGerfo, F.W.; Horton, E.S.; Veves, A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999, 48, 1856–1862. [Google Scholar] [CrossRef] [PubMed]
  43. Andersen, K.; Pedersen, B.K. The role of inflammation in vascular insulin resistance with focus on IL-6. Horm. Metab. Res. 2008, 40, 635–639. [Google Scholar] [CrossRef]
  44. Wasserman, D.H.; Wang, T.J.; Brown, N.J. The vasculature in prediabetes. Circ. Res. 2018, 122, 1135–1150. [Google Scholar] [CrossRef] [PubMed]
  45. Ormazabal, V.; Nair, S.; Elfeky, O.; Aguayo, C.; Salomon, C.; Zuñiga, F.A. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc. Diabetol. 2018, 17. [Google Scholar] [CrossRef]
  46. Katakami, N. Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus. J. Atheroscler. Thromb. 2018, 25, 27–39. [Google Scholar] [CrossRef] [Green Version]
  47. Iantorno, M.; Campia, U.; Di Daniele, N.; Nistico, S.P.; Forleo, G.B.; Cardillo, C.; Tesauro, M. Obesity, inflammation and endothelial dysfunction. J. Biol. Regul. Homeost. Agents 2014, 28, 169–176. [Google Scholar]
  48. Pannirselvam, M.; Ding, H.; Anderson, T.J.; Triggle, C.R. Pharmacological characteristics of endothelium-derived hyperpolarizing factor-mediated relaxation of small mesenteric arteries from db/db mice. Eur. J. Pharmacol. 2006, 551, 98–107. [Google Scholar] [CrossRef]
  49. Guzik, T.J.; Touyz, R.M. Oxidative Stress, Inflammation, and Vascular Aging in Hypertension. Hypertension 2017, 70, 660–667. [Google Scholar] [CrossRef]
  50. Okon, E.B.; Chung, A.W.Y.; Zhang, H.; Laher, I.; Van Breemen, C. Hyperglycemia and hyperlipidemia are associated with endothelial dysfunction during the development of type 2 diabetes. Can. J. Physiol. Pharmacol. 2007, 85, 562–567. [Google Scholar] [CrossRef]
  51. Woodman, R.J.; Chew, G.T.; Watts, G.F. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: Focus on lipid-regulating therapy. Drugs 2005, 65, 31–74. [Google Scholar] [CrossRef] [PubMed]
  52. Tschudi, M.R.; Barton, M.; Bersinger, N.A.; Moreau, P.; Cosentino, F.; Noll, G.; Malinski, T.; Lüscher, T.F. Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J. Clin. Investig. 1996, 98, 899–905. [Google Scholar] [CrossRef]
  53. Gendron, M.È.; Théorêt, J.F.; Mamarbachi, A.M.; Drouin, A.; Nguyen, A.; Bolduc, V.; Thorin-Trescases, N.; Merhi, Y.; Thorin, E. Late chronic catechin antioxidant treatment is deleterious to the endothelial function in aging mice with established atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 2010, 298. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Majithiya, J.B.; Balaraman, R. Time-dependent changes in antioxidant enzymes and vascular reactivity of aorta in streptozotocin-induced diabetic rats treated with curcumin. J. Cardiovasc. Pharmacol. 2005, 46, 697–705. [Google Scholar] [CrossRef] [PubMed]
  55. Collins, R.; Armitage, J.; Parish, S.; Sleight, P.; Peto, R. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360, 23–33. [Google Scholar] [CrossRef]
  56. Rapola, J.M.; Virtamo, J.; Haukka, J.K.; Heinonen, O.P.; Albanes, D.; Taylor, P.R.; Huttunen, J.K. Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial. JAMA 1996, 275, 693–698. [Google Scholar] [CrossRef]
  57. Daiber, A.; Chlopicki, S. Revisiting pharmacology of oxidative stress and endothelial dysfunction in cardiovascular disease: Evidence for redox-based therapies. Free Radic. Biol. Med. 2020, 157, 15–37. [Google Scholar] [CrossRef]
  58. Kowaluk, E.A.; Seth, P.; Fung, H.L. Metabolic activation of sodium nitroprusside to nitric oxide in vascular smooth muscle. J. Pharmacol. Exp. Ther. 1992, 262, 916–922. [Google Scholar]
  59. Matsushita, M.; Tanaka, Y.; Koike, K. Studies on the mechanisms underlying beta-adrenoceptor-mediated relaxation of rat abdominal aorta. J. Smooth Muscle Res. 2006, 42, 217–225. [Google Scholar] [CrossRef] [Green Version]
  60. Chai, Q.; Liu, Z.; Chen, L. Effects of streptozotocin-induced diabetes on Kv channels in rat small coronary smooth muscle cells. Chin. J. Physiol. 2005, 48, 57–63. [Google Scholar]
  61. Pelligrino, D.A.; Koenig, H.M.; Wang, Q.; Albrecht, R.F. Protein kinase C suppresses receptor-mediated pial arteriolar relaxation in the diabetic rat. Neuroreport 1994, 5, 417–420. [Google Scholar] [CrossRef]
  62. Bubolz, A.H.; Li, H.; Wu, Q.; Liu, Y. Enhanced oxidative stress impairs cAMP-mediated dilation by reducing Kv channel function in small coronary arteries of diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H1873–H1880. [Google Scholar] [CrossRef] [PubMed]
  63. Chai, Q.; Xu, X.; Jia, Q.; Dong, Q.; Liu, Z.; Zhang, W.; Chen, L. Molecular basis of dysfunctional K V channels in small coronary artery smooth muscle cells of streptozotocin-induced diabetic rats. Chin. J. Physiol. 2007, 50, 171–177. [Google Scholar] [PubMed]
  64. Jin, N.; Packer, C.S.; Rhoades, R.A. Reactive oxygen-mediated contraction in pulmonary arterial smooth muscle: Cellular mechanisms. Can. J. Physiol. Pharmacol. 1991, 69, 383–388. [Google Scholar] [CrossRef] [PubMed]
  65. Waypa, G.B.; Schumacker, P.T. Hypoxia-induced changes in pulmonary and systemic vascular resistance: Where is the O2 sensor? Respir. Physiol. Neurobiol. 2010, 174, 201–211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Bhattacharya, I.; Mundy, A.L.; Widmer, C.C.; Kretz, M.; Barton, M. Regional heterogeneity of functional changes in conduit arteries after high-fat diet. Obesity 2008, 16, 743–748. [Google Scholar] [CrossRef]
  67. Shi, Y.; Ku, D.D.; Man, R.Y.; Vanhoutte, P.M. Augmented EDHF-mediated relaxations attenuate endothelial dysfunction in femoral and mesenteric, but not in carotid arteries from type I diabetic rats. J. Pharmacol. Exp. Ther. 2006. [Google Scholar] [CrossRef]
  68. Bagi, Z.; Koller, A.; Kaley, G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am. J. Physiol.-Heart Circ. Physiol. 2004, 286, H742–H748. [Google Scholar] [CrossRef] [Green Version]
  69. Pagano, P.J.; Griswold, M.C.; Najibi, S.; Marklund, S.L.; Cohen, R.A. Resistance of endothelium-dependent relaxation to elevation of O(-)(2) levels in rabbit carotid artery. Am. J. Physiol. 1999, 277, H2109–H2114. [Google Scholar] [CrossRef] [Green Version]
  70. Liaudet, L.; Vassalli, G.; Pacher, P. Role of peroxynitrite in the redox regulation of cell signal transduction pathways. Front. Biosci. 2009, 14, 4809–4814. [Google Scholar] [CrossRef] [Green Version]
  71. Beckman, J.S. Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol. 1996, 9, 836–844. [Google Scholar] [CrossRef] [PubMed]
  72. Wei, E.P.; Kontos, H.A.; Beckman, J.S. Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite. Am. J. Physiol. 1996, 271, H1262–H1266. [Google Scholar] [CrossRef] [PubMed]
  73. Hong, K.W.; Rhim, B.Y.; Lee, W.S.; Jeong, B.R.; Kim, C.D.; Shin, Y.W. Release of superoxide-dependent relaxing factor(s) from endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 1989, 257. [Google Scholar] [CrossRef] [PubMed]
  74. Benkusky, N.A. Attenuation of vascular relaxation after development of tachyphylaxis to peroxynitrite in vivo. Am. J. Physiol. Heart Circ. Physiol. 1998, 275. [Google Scholar] [CrossRef]
  75. Nossaman, B.D.; Dabisch, P.A.; Liles, J.T.; Baber, S.R.; Champion, H.C.; Kaye, A.D.; Feng, C.-J.; Anwar, M.; Bivalacqua, T.J.; Santiago, J.A.; et al. Peroxynitrite does not impair pulmonary and systemic vascular responses. J. Appl. Physiol. 2004, 96, 455–462. [Google Scholar] [CrossRef]
  76. Villa, L.M.; Salas, E.; Darley-Usmar, V.M.; Radomski, M.W.; Moncada, S. Peroxynitrite induces both vasodilatation and impaired vascular relaxation in the isolated perfused rat heart. Proc. Natl. Acad. Sci. USA 1994, 91, 12383–12387. [Google Scholar] [CrossRef] [Green Version]
  77. Wu, M.; Pritchard, K.A.; Kaminski, P.M.; Fayngersh, R.P.; Hintze, T.H.; Wolin, M.S. Involvement of nitric oxide and nitrosothiols in relaxation of pulmonary arteries to peroxynitrite. Am. J. Physiol. 1994, 266, H2108–H2113. [Google Scholar] [CrossRef]
  78. Richardson, R.S.; Donato, A.J.; Uberoi, A.; Wray, D.W.; Lawrenson, L.; Nishiyama, S.; Bailey, D.M. Exercise-induced brachial artery vasodilation: Role of free radicals. Am. J. Physiol.-Heart Circ. Physiol. 2007, 292, H1516–H1522. [Google Scholar] [CrossRef]
  79. Dabisch, P.A.; Liles, J.T.; Baber, S.R.; Golwala, N.H.; Murthy, S.N.; Kadowitz, P.J. Analysis of L-NAME-dependent and -resistant responses to acetylcholine in the rat. Am. J. Physiol.-Heart Circ. Physiol. 2008, 294, H688–H698. [Google Scholar] [CrossRef] [Green Version]
  80. Ohashi, M.; Faraci, F.; Heistad, D. Peroxynitrite hyperpolarizes smooth muscle and relaxes internal carotid artery in rabbit via ATP-sensitive K+ channels. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H2244–H2250. [Google Scholar] [CrossRef]
  81. Lewis, S.J.; Hoque, A.; Walton, T.M.; Kooy, N.W. Potential role of nitration and oxidation reactions in the effects of peroxynitrite on the function of β-adrenoceptor sub-types in the rat. Eur. J. Pharmacol. 2005, 518, 187–194. [Google Scholar] [CrossRef] [PubMed]
  82. Hill, C.E.; Phillips, J.K.; Sandow, S.L. Heterogeneous control of blood flow amongst different vascular beds. Med. Res. Rev. 2001, 21, 1–60. [Google Scholar] [CrossRef]
  83. Goto, K.; Kitazono, T. Endothelium-dependent hyperpolarization (EDH) in diabetes: Mechanistic insights and therapeutic implications. Int. J. Mol. Sci. 2019, 20, 3737. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Pannirselvam, M.; Verma, S.; Anderson, T.J.; Triggle, C.R. Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db -/-) mice: Role of decreased tetrahydrobiopterin bioavailability. Br. J. Pharmacol. 2002, 136, 255–263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Lin, D.; Takemoto, D.J. Oxidative activation of protein kinase Cγ through the C1 domain: Effects on gap junctions. J. Biol. Chem. 2005, 280, 13682–13693. [Google Scholar] [CrossRef] [Green Version]
  86. Mulvany, M.J.; Halpern, W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ. Res. 1977, 41, 19–26. [Google Scholar] [CrossRef] [Green Version]
Ijms 21 06147 g001 550
Figure 1. Age-related changes in diabetic status and endothelial dysfunction in db/db mice. Plasma glucose (a) and insulin (b) levels following an intraperitoneal injection of glucose in db/db and control mice at six, 10, or 16 weeks of age (n = 6–10; areas under the curve (AUCs) were compared by two-way ANOVA followed by Bonferroni post-test). (c) Histogram of plasma 8-isoprostane levels in db/db and control mice at six, 10, or 16 weeks of age (n = 5–10; two-way ANOVA followed by Bonferroni post-test). Cumulative concentration–response curves of acetylcholine in the aortae (d), carotid arteries (e), and femoral arteries (f) of db/db and control mice at 6–8 weeks, 10–14 weeks, and 16–20 weeks of age (n = 6–10 mice; two-way repeated-measures ANOVA followed by Bonferroni post-test). Results are expressed as mean ± standard error (SE). * denotes p < 0.05 vs. age-matched control, # denotes p < 0.05 vs. db/db (6–8 weeks), @ denotes p < 0.05 vs. db/db (10–14 weeks).
Figure 1. Age-related changes in diabetic status and endothelial dysfunction in db/db mice. Plasma glucose (a) and insulin (b) levels following an intraperitoneal injection of glucose in db/db and control mice at six, 10, or 16 weeks of age (n = 6–10; areas under the curve (AUCs) were compared by two-way ANOVA followed by Bonferroni post-test). (c) Histogram of plasma 8-isoprostane levels in db/db and control mice at six, 10, or 16 weeks of age (n = 5–10; two-way ANOVA followed by Bonferroni post-test). Cumulative concentration–response curves of acetylcholine in the aortae (d), carotid arteries (e), and femoral arteries (f) of db/db and control mice at 6–8 weeks, 10–14 weeks, and 16–20 weeks of age (n = 6–10 mice; two-way repeated-measures ANOVA followed by Bonferroni post-test). Results are expressed as mean ± standard error (SE). * denotes p < 0.05 vs. age-matched control, # denotes p < 0.05 vs. db/db (6–8 weeks), @ denotes p < 0.05 vs. db/db (10–14 weeks).
Ijms 21 06147 g001
Ijms 21 06147 g002 550
Figure 2. Differential response of the aorta and carotid artery to increased oxidative burden. Cumulative concentration–response curves of acetylcholine in aortae (a) and carotid arteries (b) in the presence or absence of xanthine and xanthine oxidase or diethyldithiocarbamate of 16–20-week-old control mice (n = 5–7 mice). Traces showing acetylcholine-induced vasodilatation in absence and presence of xanthine and xanthine oxidase in aorta (c) and carotid artery (d), and in absence and presence of DCC in aorta (e) and carotid artery (f) (for traces in panels c to f: x-axis is time (minutes) and y-axis is force (mN)). Cumulative concentration–response curves of acetylcholine (g) and sodium nitroprusside (h) in the carotid arteries and aortae of 16–20-week-old mice (n = 6–10 mice). Results are displayed as mean ± SE. Dose–response curves were compared by two-way repeated-measures ANOVA followed by Bonferroni post-test. * denotes p < 0.05 vs. control aorta. DCC = diethyldithiocarbamate, X = xanthine, XO = xanthine oxidase.
Figure 2. Differential response of the aorta and carotid artery to increased oxidative burden. Cumulative concentration–response curves of acetylcholine in aortae (a) and carotid arteries (b) in the presence or absence of xanthine and xanthine oxidase or diethyldithiocarbamate of 16–20-week-old control mice (n = 5–7 mice). Traces showing acetylcholine-induced vasodilatation in absence and presence of xanthine and xanthine oxidase in aorta (c) and carotid artery (d), and in absence and presence of DCC in aorta (e) and carotid artery (f) (for traces in panels c to f: x-axis is time (minutes) and y-axis is force (mN)). Cumulative concentration–response curves of acetylcholine (g) and sodium nitroprusside (h) in the carotid arteries and aortae of 16–20-week-old mice (n = 6–10 mice). Results are displayed as mean ± SE. Dose–response curves were compared by two-way repeated-measures ANOVA followed by Bonferroni post-test. * denotes p < 0.05 vs. control aorta. DCC = diethyldithiocarbamate, X = xanthine, XO = xanthine oxidase.
Ijms 21 06147 g002
Ijms 21 06147 g003 550
Figure 3. Role of reactive oxygen species (ROS) in mediating vasodilatation in the carotid artery. (a) Cumulative concentration–response curves of acetylcholine in the carotid arteries of control and db/db mice (14–20 weeks old) in the presence or absence of tempol, catalase, or ebselen (n = 5–10 mice). (b) A representative trace showing vasodilatation after adding xanthine and xanthine oxidase to the carotid artery (n = 16 rings from six mice). (c) A representative trace showing inhibition of the vasorelaxant effect of xanthine and xanthine oxidase in the carotid artery in the presence of 4-aminopyridine (n = 4 from four mice). (d) A representative trace showing no vasodilatation after adding xanthine and xanthine oxidase to the aorta (n = 9 rings from five mice). For traces in panels b, c and d: x-axis is time (minutes) and y-axis is force (mN). 4-AP= 4-aminopyridine, Ach = acetylcholine, PE = phenylephrine, X = xanthine, XO = xanthine oxidase.
Figure 3. Role of reactive oxygen species (ROS) in mediating vasodilatation in the carotid artery. (a) Cumulative concentration–response curves of acetylcholine in the carotid arteries of control and db/db mice (14–20 weeks old) in the presence or absence of tempol, catalase, or ebselen (n = 5–10 mice). (b) A representative trace showing vasodilatation after adding xanthine and xanthine oxidase to the carotid artery (n = 16 rings from six mice). (c) A representative trace showing inhibition of the vasorelaxant effect of xanthine and xanthine oxidase in the carotid artery in the presence of 4-aminopyridine (n = 4 from four mice). (d) A representative trace showing no vasodilatation after adding xanthine and xanthine oxidase to the aorta (n = 9 rings from five mice). For traces in panels b, c and d: x-axis is time (minutes) and y-axis is force (mN). 4-AP= 4-aminopyridine, Ach = acetylcholine, PE = phenylephrine, X = xanthine, XO = xanthine oxidase.
Ijms 21 06147 g003
Ijms 21 06147 g004 550
Figure 4. Role of potassium channels in mediating acetylcholine-induced vasodilatation in the carotid artery. (a) Cumulative concentration–response curves of acetylcholine in the carotid arteries of control mice (14–20 weeks old) in the presence or absence of 4-aminopyridine, glybenclamide, barium, or the combination of charybdotoxin and apamin (n = 5–10 mice). (b) Cumulative concentration–response curves of acetylcholine in the carotid arteries of control mice (14–20 weeks old) in the presence or absence of 4-aminopyridine, ebselen, or their combination (n= 5–10 mice). Results are displayed as mean ± SE. Dose–response curves were compared by two-way repeated-measures ANOVA followed by Bonferroni post-test. ACh Emax was compared by one-way ANOVA. * denotes p < 0.05 vs. control carotid. 4-AP = 4-aminpyridine, CHTX = charybdotoxin.
Figure 4. Role of potassium channels in mediating acetylcholine-induced vasodilatation in the carotid artery. (a) Cumulative concentration–response curves of acetylcholine in the carotid arteries of control mice (14–20 weeks old) in the presence or absence of 4-aminopyridine, glybenclamide, barium, or the combination of charybdotoxin and apamin (n = 5–10 mice). (b) Cumulative concentration–response curves of acetylcholine in the carotid arteries of control mice (14–20 weeks old) in the presence or absence of 4-aminopyridine, ebselen, or their combination (n= 5–10 mice). Results are displayed as mean ± SE. Dose–response curves were compared by two-way repeated-measures ANOVA followed by Bonferroni post-test. ACh Emax was compared by one-way ANOVA. * denotes p < 0.05 vs. control carotid. 4-AP = 4-aminpyridine, CHTX = charybdotoxin.
Ijms 21 06147 g004
Ijms 21 06147 g005 550
Figure 5. Generalized vascular dysfunction in in the aortae of db/db mice. (a) Effects of apocynin, indomethacin, L-NAME, and tempol on ACh-induced vasodilatation in the aortae of db/db mice at 16–20 weeks of age (n = 5–10 mice). (b) Cumulative concentration–response curves of sodium nitroprusside in the aortae of db/db mice at 16–20 weeks of age (n = 6–10 mice). (c) Cumulative concentration–response curves of isoprenaline in the aortae of db/db mice at 16–20 weeks of age (n = 5 mice). Values are displayed as mean ± SE. Dose–response curves were compared by two-way repeated-measures ANOVA followed by Bonferroni post-test. Emax was compared by one-way ANOVA. * denotes p < 0.05 vs. control aorta (16–20 weeks), # denotes p < 0.05 vs. db/db aorta (16–20 weeks).
Figure 5. Generalized vascular dysfunction in in the aortae of db/db mice. (a) Effects of apocynin, indomethacin, L-NAME, and tempol on ACh-induced vasodilatation in the aortae of db/db mice at 16–20 weeks of age (n = 5–10 mice). (b) Cumulative concentration–response curves of sodium nitroprusside in the aortae of db/db mice at 16–20 weeks of age (n = 6–10 mice). (c) Cumulative concentration–response curves of isoprenaline in the aortae of db/db mice at 16–20 weeks of age (n = 5 mice). Values are displayed as mean ± SE. Dose–response curves were compared by two-way repeated-measures ANOVA followed by Bonferroni post-test. Emax was compared by one-way ANOVA. * denotes p < 0.05 vs. control aorta (16–20 weeks), # denotes p < 0.05 vs. db/db aorta (16–20 weeks).
Ijms 21 06147 g005
Ijms 21 06147 g006 550
Figure 6. Impaired vasodilatation in the femoral arteries of db/db mice. Cumulative concentration–response curves of acetylcholine in the femoral arteries of control mice (a) and db/db mice (b) at 6–8 weeks old in the presence or absence of L-NAME and indomethacin or KCl (n = 7–10). (c) Relative contribution of nitric oxide synthase (NOS)- and cyclooxygenase (COX)-resistant component and KCl-resistant component to acetylcholine-induced vasodilatation in control and db/db mice, as reflected by their respective area under the curve (AUC). (d) Cumulative concentration–response curves of acetylcholine in the presence of L-NAME and indomethacin in the femoral arteries of control and db/db mice at 6–8 weeks, 10–14 weeks, and 16–20 weeks of age (n = 7–10 mice). (e) Effects of apocynin, indomethacin, and sulfaphenazole on acetylcholine-induced vasodilatation in the femoral arteries of db/db mice at 16–20 weeks of age (n = 5–10 mice). (f) Cumulative concentration–response curves of sodium nitroprusside (SNP) in the femoral arteries of db/db at 16–20 weeks old (n = 6–10 mice). Values are displayed as mean ± SE. Dose–response curves were compared by two-way repeated-measures ANOVA followed by Bonferroni post-test. Areas under the curve were compared by two-way ANOVA followed by Bonferroni post-test. * denotes p < 0.05 vs. control femoral, # denotes p < 0.05 vs. db/db femoral. AUC = area under the curve, COX = cyclo-oxygenase, IND = indomethacin, L-N = L-NAME, NOS = nitric oxide synthase.
Figure 6. Impaired vasodilatation in the femoral arteries of db/db mice. Cumulative concentration–response curves of acetylcholine in the femoral arteries of control mice (a) and db/db mice (b) at 6–8 weeks old in the presence or absence of L-NAME and indomethacin or KCl (n = 7–10). (c) Relative contribution of nitric oxide synthase (NOS)- and cyclooxygenase (COX)-resistant component and KCl-resistant component to acetylcholine-induced vasodilatation in control and db/db mice, as reflected by their respective area under the curve (AUC). (d) Cumulative concentration–response curves of acetylcholine in the presence of L-NAME and indomethacin in the femoral arteries of control and db/db mice at 6–8 weeks, 10–14 weeks, and 16–20 weeks of age (n = 7–10 mice). (e) Effects of apocynin, indomethacin, and sulfaphenazole on acetylcholine-induced vasodilatation in the femoral arteries of db/db mice at 16–20 weeks of age (n = 5–10 mice). (f) Cumulative concentration–response curves of sodium nitroprusside (SNP) in the femoral arteries of db/db at 16–20 weeks old (n = 6–10 mice). Values are displayed as mean ± SE. Dose–response curves were compared by two-way repeated-measures ANOVA followed by Bonferroni post-test. Areas under the curve were compared by two-way ANOVA followed by Bonferroni post-test. * denotes p < 0.05 vs. control femoral, # denotes p < 0.05 vs. db/db femoral. AUC = area under the curve, COX = cyclo-oxygenase, IND = indomethacin, L-N = L-NAME, NOS = nitric oxide synthase.
Ijms 21 06147 g006
Ijms 21 06147 g007 550
Figure 7. Protein expression of superoxide dismutase (SOD) isoforms in the aortae, as well as carotid and femoral arteries, of db/db (red filling) and control mice (white filling) (16–20 weeks old) (n = 4). Results are displayed as mean ± SE. Relative band intensities were compared by two-way ANOVA followed by Bonferroni post-test. * denotes p < 0.05 vs. control aorta, # denotes p < 0.05 vs. control femoral, @ denotes p < 0.05 vs. db/db aorta, α denotes p < 0.05 vs. db/db femoral artery. SOD = superoxide dismutase.
Figure 7. Protein expression of superoxide dismutase (SOD) isoforms in the aortae, as well as carotid and femoral arteries, of db/db (red filling) and control mice (white filling) (16–20 weeks old) (n = 4). Results are displayed as mean ± SE. Relative band intensities were compared by two-way ANOVA followed by Bonferroni post-test. * denotes p < 0.05 vs. control aorta, # denotes p < 0.05 vs. control femoral, @ denotes p < 0.05 vs. db/db aorta, α denotes p < 0.05 vs. db/db femoral artery. SOD = superoxide dismutase.
Ijms 21 06147 g007

Share and Cite

MDPI and ACS Style

Sallam, N.A.; Laher, I. Redox Signaling and Regional Heterogeneity of Endothelial Dysfunction in db/db Mice. Int. J. Mol. Sci. 2020, 21, 6147. https://doi.org/10.3390/ijms21176147

AMA Style

Sallam NA, Laher I. Redox Signaling and Regional Heterogeneity of Endothelial Dysfunction in db/db Mice. International Journal of Molecular Sciences. 2020; 21(17):6147. https://doi.org/10.3390/ijms21176147

Chicago/Turabian Style

Sallam, Nada A., and Ismail Laher. 2020. "Redox Signaling and Regional Heterogeneity of Endothelial Dysfunction in db/db Mice" International Journal of Molecular Sciences 21, no. 17: 6147. https://doi.org/10.3390/ijms21176147

APA Style

Sallam, N. A., & Laher, I. (2020). Redox Signaling and Regional Heterogeneity of Endothelial Dysfunction in db/db Mice. International Journal of Molecular Sciences, 21(17), 6147. https://doi.org/10.3390/ijms21176147

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop